Back to News
Market Impact: 0.2
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Source: Business Wire
Healthcare & BiotechPrivate Markets & VentureArtificial Intelligence
Schrödinger announced the formation of Tectora, a biotechnology company co-founded with NEA and RA Capital to develop therapies for immunology and inflammation. The new venture expands Schrödinger's biotech ecosystem and provides a vehicle for advancing potential AI-enabled drug-discovery programs, though no funding amount, pipeline assets, or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
SDGR0.55
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong
- Brookfield to open Qatar office as it expands Middle East operations
- Xencor reports phase 1 data for cancer drug XmAb819
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework